gefitinib,Osimertinib
astrazeneca
['lung', 'nsclc', 'sclc', 'gefitinib']
apple phase ii trial of gefitinib vs gefitinib + ctdna testing in mnsclc with egfr mutation. testing for t790m ctdna was feasible. no major differences in pfs or os. clearance of ctdna predicts better pfs. #esmo2022 #lungcancer
Medical oncologist treating thoracic cancer and researching treatment disparities, cancer, aging, and frailty. he/him, views my own.